Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

See more here


Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

– Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions 

– Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease

– Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders

– We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 dilated cardiomyopathy

– Expected to add approximately $38M in projected cash at closing; combined with recent $26M ATM sale, extends cash runway into 2Q’24

– Webcast to be held at 8:00 a.m. E.T. today, Sept. 20

See more here


Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington’s Disease and Prion Diseases

See more here


Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders

Series A financing round, led by Deerfield Management, to accelerate a new cell therapy modality for the treatment of neurological disorders, including Parkinson’s Disease

See more here


Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

See more here


Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

The study demonstrates the importance of tumor and lymph node-derived B cells for the discovery of antibodies directed at potentially novel targets

– The study results provide a framework for understanding the evolution of B cell families in cancer patients

See more here


Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

See more here


InfraScan Inc. Announces Publication of the Largest Study to date for TBI Diagnosis Utilizing NIRD

Duke Global Neurosurgery and Neurology publishes its independent results from the largest U.S.-based study using a near-infrared device (NIRD) to detect hemorrhage due to Traumatic Brain Injuries (TBI).

See more here


Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

See more here